Updated on 8 October 2012
The value of the contract is approximately $3.2 million
Singapore: AtCor Medical, developer and marketer of the SphygmoCor system which measures central aortic blood pressures and arterial stiffness non-invasively, has signed a contract to supply SphygmoCor systems and clinical trial support services to a major international pharmaceutical company. Systems will be placed at sites throughout Europe and North America. The value of the contract is approximately $3.2 million.
"We are delighted to have secured this significant contract. This, together with the pharmaceutical contract announced in August, represents a very good start to our financial year," said Mr Duncan Ross, CEO of AtCor Medical. "This contract is with an existing client that we have worked with for a number of years. The non-invasive measurement of central blood pressure and arterial stiffness is particularly important for drug development, which requires accurate, insightful data to fully understand the efficacy of new drugs. It is encouraging that AtCor's gold standard technology, data management and support services are being validated through repeat business from the pharmaceutical sector."
The company's technology has been featured in over 600 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the US, and Europe.